EISAI CO LTD | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (34)

View All

Latest Posts

About This Stock More About This Stock
Current Analysis: Eisai Co Ltd (ESAIY)
Article By: Fredrik Arnold
Sunday, July 16, 2023 10:28 PM EDT
Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price.
In this article: ESALF, ESAIY
Read
Week In Review: Eddingpharm Pays $169 Million For China Rights To Omega-3 Drug
Article By: ChinaBio® Today
Sunday, March 1, 2015 5:52 PM EDT
Eddingpharm, a China in-licensing company, signed a deal worth up to $169 million for China rights to Vascepa®, a prescription omega-3 drug from Amarin Corp and more Pharma/Biotech news.
In this article: AMRN, ESALF, ESALY, TEVA
Read
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Article By: The Life Sciences Report
Friday, January 23, 2015 5:48 PM EDT
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. Edward Stopke of Sagient Research unveils his list of companies with catalytic moments in the making.
In this article: PSTV, VCEL, ATHX, BLUE, CUR, KITE, NVS, AMGN, JUNO, RNN, MRK, ESALF, RPTP, CLDX, SRPT, PTCT, GILD, RMTI
Read
Shares Of Arena Pharmaceuticals Soar 65% After Early Positive Results In Autoimmune Diseases
Article By: Terry Chrisomalis
Wednesday, January 7, 2015 2:24 PM EDT
Drug shows promise in decreasing lymphocyte count.
In this article: ARNA, ESALF
Read
All Posts

Latest Tweets for $ESALF

No tweets yet!

PARTNER HEADLINES